# The U.S. Food and Drug Administration has approved Merck's Idvynso (doravirine/islatravir) The approval is based on data from two randomized, active-controlled, noninferiority trials.

*biotech · news · 2026-05-02 · Medical Xpress*

## Key points

- The FDA has approved Merck's Idvynso, a once-daily two-drug HIV-1 treatment tablet.
- Idvynso showed noninferior efficacy to current regimens in phase 3 trials, with 1% viral rebound at 48 weeks.
- Idvynso cannot be used with strong CYP3A enzyme inducers, lamivudine, or emtricitabine.
- Idvynso is the first approved two-drug, non-integrase inhibitor, tenofovir-free regimen for HIV-1 in adults.

**Companies:** Merck
**Countries:** United States

[Read the full story on Medical Xpress](https://medicalxpress.com/news/2026-05-fda-daily-idvynso-tablet-hiv.html)

---

Canonical: https://newsio.io/n/4b6b17c9-26ef-4394-a07b-a1d41d659fc5/the-u-s-food-and-drug-administration-has-approved-mercks-idvynso-doravirineislat
Summarized by Newsio from Medical Xpress. https://newsio.io/how-it-works